NASDAQ · OPHTHALMIC GOODS · LARGE CAP
Staar Surgical Co. STAA
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$239.4M
▼ 23.7% vs FY2024
EPS · FY25
$-1.62
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-21.7%
Net margin · FY25
-33.6%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 239.4M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
The company lost 34 cents on every revenue dollar this year.
Per share
USD -1.62
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-21.7%
Return on equity, FY2025
ROE
Operating margin-38.3%
Net margin-33.6%
Return on assets-16.7%
Each USD of equity lost 22 cents this year.
Returned to shareholders
USD 3.0M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 3.0M
Share of profit-3.7%
Consecutive raises—
USD 3.0M in buybacks went back to shareholders in a year without profit.
Growth
+7.9% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+0.0%
+7.9%
+12.0%
+10.3%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.05B
Shares outstanding, FY2025
Change, 5 years+6.3%
Change, 10 years—
The share count grew 6% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 451.7M
total assets, end of FY2025
Total assetsUSD 451.7M
EquityUSD 344.2M
CashUSD 153.2M
Current ratio4.55×
Equity funds 76% of total assets.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.2
0.3
0.3
0.2
0.2
0.2
0.2
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
Operating income $B
−0.1
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
0.0
−0.0
−0.0
EBITDA $B
−0.1
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
−0.0
−0.0
Income tax $B
−0.0
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
−0.0
−0.0
0.0
−0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.1
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
0.0
0.0
−0.0
EPS, diluted $
−1.62
−0.41
0.43
0.80
0.56
0.12
0.30
0.11
−0.05
−0.30
−0.17
−0.22
0.01
−0.05
0.04
0.00
−0.19
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−21.7
−5.2
5.9
13.3
12.0
3.3
9.6
5.7
−5.3
−31.6
−17.2
−22.1
1.1
−5.8
5.2
0.2
−29.4
Shares out B
0.05
0.05
0.05
0.05
0.05
0.05
0.04
0.04
0.04
0.00
0.00
0.00
0.00
0.04
0.04
0.04
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
65 of 65
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed